Thursday, August 29, 2019 10:18:05 AM
Details of the condition here:
https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Charcot-Marie-Tooth-Disease-Fact-Sheet
Might this disease be successfully treated with an Anavex sigma-1 receptor agonist? Quite possible. Importantly, although genetic, CMT symptoms have a post-natal (after birth) onset, usually in early or late childhood. For a time, nerves work adequately, then begin to degenerate.
Certainly the Anavex drugs will be tested in transgenic rats with the CMT genes. And, because of no appreciable (well, any) side effects, the drug could certainly be given to children with the CMT genes in an attempt to slow or prohibit symptomatic onset. Perhaps Anavex drugs can maintain various neuronal homeostatic processes that normally maintain neuron function (ones lost with the progression of CMT).
Interestingly, I, myself, have a very mild form of a somewhat related disease, hereditary spastic paraplegia (HSP). In kindergarten, my teacher Mrs. Dillenschneider became angered at me because I absolutely refused to sit cross-legged on the floor while she read to us stories. Instead, I laid on my side or belly, with legs fully extended.
At the time, no one, Mrs. Dillenschneider, my parents, or me, understood the problem of my non-compliance. My HSP was starting to set in. In HSP (among other symptoms) the long motor nerves in the spinal cord that control the muscles of the upper leg, particularly the adductors, become chronically hyperactive. This draws the legs together, making it impossible to sit cross-legged. Spasticity.
Fortunately, of the over 60 phenotypes of HSP (in fact, there may be hundreds), I have one of the least problematic. I went on to play basketball and other sports. I simply walked a bit funny, a bit pigeon-toed.
But the disease progressed. In the last 10 years (I’m in my 70s now) my leg spasticity has increased; and I have urinary retention, inability of the bladder to completely void during urination. A typical HSP symptom. I now have to deal with a suprapubic catheter — which I manage well, maintaining aseptic replacement, etc. My urologist is a former student of mine. He commends me on several catheter innovations I’ve adopted; ones he’s demonstrated to his nurses and other catheter patients.
For me (and my HSP) here’s where Anavex enters. A few years ago I found a journal article (I believe from France) where transgenic rats with HSP symptoms (back leg spasticity, etc.) were allowed to drink Anavex 2-73-laden water ad libidum. In just a week or so, each of the rats began walking and urinating normally. The Anavex drug suppressed the motor neuron hyperexitability.
Alarmingly, for me at least, I unknowingly lost my digital copy of this study during a computer file transfer. I later tried to retrieve it; gone, no where to be found. I’ve tried searching through the many sigma-1 receptor agonist papers on the internet, but have not be able to find it. It’s very obscure. If anyone knows of the paper, please post it. With it in hand, I will be able to prompt my neurologist to write an off-label prescription for Anavex 2-73 when it gains sales approval. My insurance company won’t pay for that prescription. It’ll cost me probably thousands. But in the case of the transgenic HSP rats, the restored neuron function appeared to endure for some time after therapy was terminated (as I recall).
Where is the HSP rat study paper? Anyone? People with CMT, too, would like to show it to their neurologists when Anavex 2-73 is on pharmacy shelves.
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM